The Asia-Pacific Molecular Diagnostics Market is projected to reach $11.87 billion by 2030, at a CAGR of 7.2% from 2023 to 2030. Molecular diagnostics help detect the targeted genetic material in human, viral, and bacterial genomes. Molecular diagnostic tests are increasingly used in many areas, including infectious diseases, oncology, and clinical genetics. Advancements in molecular diagnostics continue to improve the accuracy and speed of diagnosis. Molecular diagnostics is becoming an essential aspect of patient-tailored interventions and therapeutics. The molecular diagnostics market comprises advanced products and technologies used by medical professionals for patient management, from diagnosis to treatment, primarily focusing on areas such as infectious diseases and cancer.
Asia-Pacific molecular diagnostics market is growing due to the rising healthcare expenditure, growing use of PoC diagnostics tests, technological advancements in molecular diagnostics, and increasing funding for R&D in molecular diagnostics. Furthermore, increasing focus on companion diagnostics to offer new growth potential is expected to offer immense growth opportunities for market expansion. However, stringent regulatory frameworks and the high cost of molecular diagnostics tests are expected to restrain the growth of this market to some extent. In addition, the lack of skilled professionals is a major challenge to the market’s growth.
The development of molecular diagnostic systems or assays requires significant capital investments. Thus, financial support in the form of funding is essential to develop and bring the technology into the market. Several organizations are funding many molecular diagnostic devices in the developmental phase. Some of the key companies are receiving funding that helped them focus on developing molecular diagnostics products. For instance,
In July 2021, MiRXES Pte Ltd (Singapore) raised USD 77 million in Series C funding, led by CR-CP Life Science Fund (Thailand) and Keytone Ventures. The funds are being used to deliver cancer early detection tests and preventive healthcare across the globe.
Thus, such initiatives are driving the market’s growth.
Click here to: Get Free Sample Pages of this Report
The healthcare landscape is constantly changing due to innovations in medical technologies. In recent years, companies have been focused on developing advanced diagnostic kits that can allow faster results than traditional kits. These advanced kits enable healthcare providers and caregivers to make crucial medical decisions promptly. Companies have been developing ultra-fast PCR kits to minimize the time required to generate test results. For instance, In November 2021, Genes2Me (India) launched an RT-PCR kit for COVID-19 that shows results in 40 minutes without any instrument and RNA extraction kit. Similarly, Genesystem (South Korea) launched the ultra-fast GENECHECKER UF-300 real-time PCR system to detect novel coronavirus infections. This ultra-fast PCR kit received the CE mark approval in April 2020. The total turnaround time using the GENECHECKER UF-300 real-time PCR platform is 45 minutes.
Furthermore, integrating digital technologies in clinical and ambulatory settings helps improve doctors’ and physicians’ ability to reach an initial diagnosis. Also, the digitalization of diagnostic services helps document and analyze patient data and test results, which minimizes human error and makes treatment and care pathways more consistent. Hence, an increasing number of healthcare providers are adopting digitally compatible diagnostic systems and devices to store patient data and view patients’ medical histories instantly.
Key Findings of the Asia-Pacific Molecular Diagnostics Market Study:
In 2023, the Kits & Reagents Segment is Expected to Dominate the Molecular Diagnostics Market
Among all the products & services covered in the report, in 2023, the kits & reagents segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, rise in product approvals, and technological advancements in molecular techniques contribute to the large market share of this segment.
In 2023, the Laboratory Tests Segment is Expected to Dominate the Molecular Diagnostics Market
Among all the test types covered in the report, in 2023, the lab tests segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. Lab tests are traditionally used in hospitals and diagnostic centers and are widely accepted. Laboratory testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. It has higher accuracy and reliability when compared to point-of-care testing. The laboratory equipment and analyzers have high sensitivity and specificity. These factors drive the adoption of laboratory tests.
In 2023, the Polymerase Chain Reaction (PCR) Segment is Expected to Dominate the Asia-Pacific Molecular Diagnostics Market
Among all the technologies covered in the report, in 2023, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. The large market share of this segment is attributed to its benefits, such as the ability to test for multi-drug resistance, ease of quantification, greater sensitivity, rapid results compared to traditional diagnostics methods, and launches of PCR kits in the region for the qualitative and quantitative detection of COVID infections. In May 2021, Cipla Inc. (India) launched ViraGen, an RT-PCR test kit for the detection of coronavirus.
In 2023, the Infectious Diseases Segment is Expected to Dominate the Asia-Pacific Molecular Diagnostics Market
Among all the applications covered in the report, in 2023, the infectious diseases segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. Infectious diseases are transmissible or communicable illnesses that spread quickly in some areas and become epidemics. It is crucial to quickly diagnose initial infections and prevent further spread through in vitro diagnosis. The growing prevalence of infectious diseases such as HIV, the growing availability of rapid and self-diagnostic tests for HIV, the rising funds for infectious disease diagnostic research activities, the emergence of the COVID-19 pandemic, and the growing need to detect and treat infectious diseases have led to the emergence of new technologies such as molecular systems and PoC, microarrays, and next-generation sequencing are the factors attributed to the segment’s large market share.
In 2023, the Hospitals & Clinics Segment is Expected to Dominate the Molecular Diagnostics Market
Among all the end users covered in the report, in 2023, the hospitals & clinics segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. The segment's large market share is attributed to the increased number of hospitalizations due to various diseases requiring molecular diagnosis, the high prevalence of healthcare-associated infections (HAIs) among individuals, growing awareness of the importance of molecular diagnostics and governments of various countries in the region are supporting hospitals by providing funds. In February 2020, the Maharashtra government (India) announced that it would set up a COVID-19 testing facility at Kasturba Hospital (Mumbai) to reduce the burden of testing at the National Institute of Virology (Pune).
China: Largest Share of the Market
Among all the countries covered in the report, in 2023, China is expected to account for the largest share of the Asia-Pacific molecular diagnostics market due to the rising geriatric population and growing prevalence of infectious & chronic diseases. The elderly population is more prone to chronic and infectious diseases due to immune dysfunction, malnutrition, and physiological changes associated with aging. The rising burden of diseases can directly affect the social and economic status of a country. Thus, it is necessary to adopt early diagnostic procedures to minimize the burden of these diseases. The high population growth, the rise in the geriatric population, and the rising prevalence of diseases have increased the demand for molecular diagnostic products in the country.
Key Players
The key players profiled in the Asia-Pacific molecular diagnostics market study are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), and Seegene, Inc. (South Korea).
Scope of the Report:
Asia-Pacific Molecular Diagnostics Market Assessment, by Product & Services
Asia-Pacific Molecular Diagnostics Market Assessment, by Test Type
Asia-Pacific Molecular Diagnostics Market Assessment, by Technology
Asia-Pacific Molecular Diagnostics Market Assessment, by Application
Asia-Pacific Molecular Diagnostics Market Assessment, by End User
Asia-Pacific Molecular Diagnostics Market Assessment, by Country/Region
Key questions answered in the report:
The Asia-Pacific molecular diagnostics market study covers the market sizes and forecasts for various molecular diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the Asia-Pacific molecular diagnostics market at the country level.
The Asia-Pacific molecular diagnostics market is projected to reach $11.87 billion by 2030, at a CAGR of 7.2% during the forecast period.
In 2023, the kits & reagents segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. The largest market share of this segment is attributed to the need for kits for the growing prevalence of diseases and the growing awareness of early diagnosis among the people.
In 2023, the hospitals & clinics segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market. The large market share of this segment is attributed to the increased number of hospitalizations due to various diseases requiring molecular diagnosis and the proliferation of hospitals and clinics in emerging countries, leading to growth in the utilization of molecular diagnostic products.
The growth of this market is driven by rising healthcare expenditure, growing use of PoC diagnostics tests, technical advancements in molecular diagnostics, and increasing funding for R&D of molecular diagnostics products. In addition, companion diagnostics offering new growth potential are expected to provide significant opportunities for the growth of this market.
The key players operating in the Asia-Pacific molecular diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), and Seegene, Inc. (South Korea).
Emerging economies from Asia-Pacific, such as China and India, are projected to offer significant growth opportunities for vendors operating in this market due to the growing awareness about infectious diseases, focus on technological advancements, increasing geriatric population, and increasing investment in the healthcare sector.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Rising Healthcare Expenditure
4.2.2. Growing Use of Point-of-Care (PoC) Diagnostic Tests
4.2.3. Technical Advancements in Molecular Diagnostics
4.2.4. Increasing Funding for R&D of Molecular Diagnostics Products
4.3. Restraints
4.3.1. Stringent Regulatory Framework
4.3.2. High Cost of Molecular Diagnostic Tests
4.4. Opportunities
4.4.1. Increasing Focus on Companion Diagnostics to Offer New Growth Potential
4.5. Challenges
4.5.1. Lack of Skilled Professionals
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Porter’s Five Forces Analysis
5. Asia-Pacific Molecular Diagnostics Market Assessment—by Product & Service
5.1. Overview
5.2. Kits & Reagents
5.3. Instruments
5.4. Software & Services
6. Asia-Pacific Molecular Diagnostics Market Assessment—by Test Type
6.1. Overview
6.2. Laboratory Tests
6.3. Point-of-Care Tests
7. Asia-Pacific Molecular Diagnostics Market Assessment—by Technology
7.1. Overview
7.2. Polymerase Chain Reaction (PCR)
7.3. In Situ Hybridization (ISH)
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Microarrays
7.6. Sequencing
7.7. Mass Spectrometry
7.8. Other Technologies
8. Asia-Pacific Molecular Diagnostics Market Assessment—by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. COVID-19
8.2.2. Hepatitis
8.2.3. HIV
8.2.4. Chlamydia Trachomatis/Neisseria Gonorrhoeae (CT/NG)
8.2.5. Human Papillomavirus (HPV)
8.2.6. Tuberculosis
8.2.7. Influenza
8.2.8. Healthcare-associated Infections (HAIs)
8.2.9. Other Infectious Diseases
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Lung Cancer
8.3.4. Prostate Cancer
8.3.5. Lymphoma
8.3.6. Leukemia
8.3.7. Cervical Cancer
8.3.8. Other Cancer Types
8.4. Genetic Testing
8.5. Neurological Diseases
8.6. Cardiovascular Diseases
8.7. Other Applications
9. Asia-Pacific Molecular Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Other End Users
10. Asia-Pacific Molecular Diagnostics Market Assessment—by Country/Region
10.1. Overview
10.2. China
10.3. India
10.4. Japan
10.5. Australia
10.6. Singapore
10.7. Indonesia
10.8. Malaysia
10.9. South Korea
10.10. New Zealand
10.11. Rest of Asia-Pacific
11. Competitive Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis, by Key Player/Key Market Ranking, 2022
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)
12.1. F. Hoffmann-La Roche Ltd.
12.2. Hologic, Inc.
12.3. QIAGEN N.V.
12.4. Danaher Corporation
12.5. bioMérieux S.A.
12.6. Becton, Dickinson and Company (BD)
12.7. Siemens Healthineers AG
12.8. DiaSorin S.p.A.
12.9. Abbott Laboratories
12.10. Thermo Fisher Scientific Inc.
12.11. Agilent Technologies, Inc.
12.12. Illumina, Inc.
12.13. Seegene, Inc.
(Note: SWOT analysis will be provided for the top 5 players only)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Asia-Pacific Molecular Diagnostics Market, by Product & Service, 2021–2030 (USD Million)
Table 2 Asia-Pacific Molecular Diagnostics Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 3 Asia-Pacific Molecular Diagnostics Instruments Market, by Country/Region, 2021–2030 (USD Million)
Table 4 Asia-Pacific Molecular Diagnostics Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 5 Asia-Pacific Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 6 Asia-Pacific Molecular Diagnostics for Laboratory Tests, by Country/Region, 2021–2030 (USD Million)
Table 7 Asia-Pacific Molecular Diagnostics for Point-of-Care Tests, by Country/Region, 2021–2030 (USD Million)
Table 8 Asia-Pacific Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 9 Asia-Pacific Molecular Diagnostics for Polymerase Chain Reaction (PCR), by Country/Region, 2021–2030 (USD Million)
Table 10 Asia-Pacific Molecular Diagnostics for In Situ Hybridization (ISH), by Country/Region, 2021–2030 (USD Million)
Table 11 Asia-Pacific Molecular Diagnostics for Isothermal Nucleic Acid Amplification Technology (INAAT), by Country/Region, 2021–2030 (USD Million)
Table 12 Asia-Pacific Molecular Diagnostics for Microarrays, by Country/Region, 2021–2030 (USD Million)
Table 13 Asia-Pacific Molecular Diagnostics for Mass Spectrometry, by Country/Region, 2021–2030 (USD Million)
Table 14 Asia-Pacific Molecular Diagnostics for Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 15 Asia-Pacific Other Technologies Market, by Country/Region, 2021–2030 (USD Million)
Table 16 Asia-Pacific Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 17 Asia-Pacific Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 18 Asia-Pacific Molecular Diagnostics Market for Infectious Diseases Market, by Country/Region, 2021–2030 (USD Million)
Table 19 Asia-Pacific Molecular Diagnostics Market for COVID-19, by Country/Region, 2021–2030 (USD Million)
Table 20 Asia-Pacific Molecular Diagnostics Market for Hepatitis, by Country/Region, 2021–2030 (USD Million)
Table 21 Asia-Pacific Molecular Diagnostics Market for HIV, by Country/Region, 2021–2030 (USD Million)
Table 22 Asia-Pacific Molecular Diagnostics Market for CT/NG, by Country/Region, 2021–2030 (USD Million)
Table 23 Asia-Pacific Molecular Diagnostics Market for Human papillomavirus (HPV), by Country/Region, 2021–2030 (USD Million)
Table 24 Asia-Pacific Molecular Diagnostics Market for Tuberculosis, by Country/Region, 2021–2030 (USD Million)
Table 25 Asia-Pacific Molecular Diagnostics Market for Influenza, by Country/Region, 2021–2030 (USD Million)
Table 26 Asia-Pacific Molecular Diagnostics Market for Healthcare-associated Infections (HAIs), by Country/Region, 2021–2030 (USD Million)
Table 27 Asia-Pacific Molecular Diagnostics Market for Other Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 28 Asia-Pacific Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 29 Asia-Pacific Molecular Diagnostics Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 30 Asia-Pacific Molecular Diagnostics Market for Breast Cancer, by Country/Region, 2021–2030 (USD Million)
Table 31 Asia-Pacific Molecular Diagnostics Market for Colorectal Cancer, by Country/Region, 2021–2030 (USD Million)
Table 32 Asia-Pacific Molecular Diagnostics Market for Lung Cancer, by Country/Region, 2021–2030 (USD Million)
Table 33 Asia-Pacific Molecular Diagnostics Market for Prostate Cancer, by Country/Region, 2021–2030 (USD Million)
Table 34 Asia-Pacific Molecular Diagnostics Market for Lymphoma, by Country/Region, 2021–2030 (USD Million)
Table 35 Asia-Pacific Molecular Diagnostics Market for Leukemia, by Country/Region, 2021–2030 (USD Million)
Table 36 Asia-Pacific Molecular Diagnostics Market for Cervical Cancer, by Country/Region, 2021–2030 (USD Million)
Table 37 Asia-Pacific Molecular Diagnostics Market for Other Cancer Types, by Country/Region, 2021–2030 (USD Million)
Table 38 Asia-Pacific Molecular Diagnostics Market for Genetic Testing, by Country/Region, 2021–2030 (USD Million)
Table 39 Asia-Pacific Molecular Diagnostics Market for Neurological Diseases, by Country/Region, 2021–2030 (USD Million)
Table 40 Asia-Pacific Molecular Diagnostics Market for Cardiovascular Diseases, by Country/Region, 2021–2030 (USD Million)
Table 41 Asia-Pacific Molecular Diagnostics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 42 Asia-Pacific Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 43 Asia-Pacific Molecular Diagnostics Market for Hospitals & Clinics, by Country/Region, 2021–2030 (USD Million)
Table 44 Asia-Pacific Molecular Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 45 Asia-Pacific Molecular Diagnostics Market for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 46 Asia-Pacific Molecular Diagnostics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 47 Asia-Pacific: Molecular Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 48 China: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 49 China: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 50 China: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 51 China: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 52 China: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 53 China: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 54 China: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 55 Japan: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 56 Japan: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 57 Japan: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 58 Japan: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 59 Japan: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 60 Japan: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 61 Japan: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 62 India: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 63 India: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 64 India: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 65 India: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 66 India: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 67 India: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 68 India: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 69 Australia: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 70 Australia: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 71 Australia: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 72 Australia: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 73 Australia: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 74 Australia: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 75 Australia: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 76 Singapore: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 77 Singapore: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 78 Singapore: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 79 Singapore: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 80 Singapore: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 81 Singapore: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 82 Singapore: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 83 Indonesia: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 84 Indonesia: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 85 Indonesia: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 86 Indonesia: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 87 Indonesia: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 88 Indonesia: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 89 Indonesia: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 90 Malaysia: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 91 Malaysia: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 92 Malaysia: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 93 Malaysia: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 94 Malaysia: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 95 Malaysia: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 96 Malaysia: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 97 South Korea: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 98 South Korea: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 99 South Korea: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 100 South Korea: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 101 South Korea: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 102 South Korea: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 103 South Korea: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 104 New Zealand: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 105 New Zealand: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 106 New Zealand: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 107 New Zealand: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 108 New Zealand: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 109 New Zealand: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 110 New Zealand: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 111 Rest of Asia-Pacific: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 112 Rest of Asia-Pacific: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 113 Rest of Asia-Pacific: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 114 Rest of Asia-Pacific: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 115 Rest of Asia-Pacific: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 116 Rest of Asia-Pacific: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 117 Rest of Asia-Pacific: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 118 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Estimation
Figure 7 Asia-Pacific Molecular Diagnostics Market, by Product/Service, 2023–2030 (USD Million)
Figure 8 Asia-Pacific Molecular Diagnostics Market, by Test Type, 2023–2030 (USD Million)
Figure 9 Asia-Pacific Molecular Diagnostics Market, by Technology, 2023–2030 (USD Million)
Figure 10 Asia-Pacific Molecular Diagnostics Market, by Application, 2023–2030 (USD Million)
Figure 11 Asia-Pacific Molecular Diagnostics Market, by End User, 2023–2030 (USD Million)
Figure 12 Asia-Pacific Molecular Diagnostics Market, by Country/Region
Figure 13 Market Dynamics: Asia-Pacific Molecular Diagnostics Market
Figure 14 Asia-Pacific Molecular Diagnostics Market, by Product/Service, 2023 Vs. 2030 (USD Million)
Figure 15 Asia-Pacific Molecular Diagnostics Market, by Test Type, 2023 Vs. 2030 (USD Million)
Figure 16 Asia-Pacific Molecular Diagnostics Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 17 Asia-Pacific Molecular Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 18 Asia-Pacific Molecular Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 19 Asia-Pacific Molecular Diagnostics Market, by Country/Region, 2023 Vs. 2030 (USD Million)
Figure 20 Asia-Pacific Molecular Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 22 Asia-Pacific Molecular Diagnostics Market: Competitive Benchmarking, by Type
Figure 23 Asia-Pacific Molecular Diagnostics Market: Competitive Dashboard
Figure 24 Asia-Pacific Molecular Diagnostics Market: Market Share Analysis (2022)
Figure 25 F. Hoffmann-La Roche Ltd: Financial Snapshot, 2022
Figure 26 Hologic, Inc.: Financial Snapshot, 2022
Figure 27 QIAGEN N.V.: Financial Snapshot, 2022
Figure 28 Danaher Corporation: Financial Snapshot, 2022
Figure 29 BioMérieux S.A.: Financial Snapshot 2022
Figure 30 Becton, Dickinson and Company: Financial Snapshot, 2022
Figure 31 Siemens Healthineers AG: Financial Snapshot, 2022
Figure 32 DiaSorin S.p.A.: Financial Snapshot, 2022
Figure 33 Abbott Laboratories: Financial Snapshot, 2022
Figure 34 Thermo Fisher Scientific Inc.: Financial Snapshot, 2022
Figure 35 Agilent Technologies, Inc.: Financial Snapshot, 2022
Figure 36 Illumina, Inc.: Financial Snapshot, 2022
Figure 37 Seegene, Inc.: Financial Snapshot, 2022
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Oct-2023
Published Date: Sep-2023
